Efficacy and safety of omalizumab in paediatric age: An update of literature data

Journal of Biological Regulators and Homeostatic Agents

Volumn 30, Issue 2, 2016, Pages 579-584

  Matin, N ^a   Tabatabaie, O ^a   Falsaperla, R ^b   Pavone, P ^b   Serra, A ^b   Cocuzza, S ^b   Di Mauro, Paola ^b   Licciardello, L ^b   Lubrano, R ^c   Vitaliti, G ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Allergic diseases; Asthma; IGE; Omalizumab; Paediatric age; Safety and efficacy

Indexed keywords

FLUTICASONE; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; ANTIALLERGIC AGENT;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; ATOPIC DERMATITIS; CHILDHOOD DISEASE; CHRONIC URTICARIA; CLINICAL EVALUATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; HEADACHE; HOSPITALIZATION; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOTHERAPY; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MULTICENTER STUDY (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SERUM SICKNESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ASTHMA; CHILD; CLINICAL TRIAL (TOPIC); DERMATITIS, ATOPIC; FOOD HYPERSENSITIVITY; URTICARIA;

ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; FOOD HYPERSENSITIVITY; HUMANS; OMALIZUMAB; URTICARIA;

EID: 84982806075     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 2011; 4:49.
2. Administration. FaD. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103976s5211lbl.pdf.
3. Information EMAEOXfp, (EU). 2007. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000606/human-med-001162.jsp&mid=WC0b01ac058001d124. 6 Aug 2013.
4. Geneva WHO. Asthma 2006 (Fact sheet No. 307). Available from: http://www.who.int/mediacentre/factsheets/fs307/en/index.html.
5. Akinbami LJ, Bailey C, Zahran HS, King M, Johnson CA, Liu X. Trends in asthma prevalence, health care use, and mortality in the United States, 2001 2010-2012. Available from: http://www.cdc.gov/nchs/data/databriefs/db94.htm#x2013;2010%3C/a%3E.
6. Engelkes M, Janssens HM, de Ridder MA, de Jongste JC, Sturkenboom MC, Verhamme KM. Time trends in the incidence, prevalence and age at diagnosis of asthma in children. Pediatr Allergy Immunol 2015; 26:367-74.
7. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:e36.
8. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long- Term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91(2):182-88.
9. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210-16.
10. Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin 2010; 26:1285-93.
11. Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2010; 27:163-69.
12. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: A 1-year real life survey. Eur Respir J 2013; 42:1224-33.
13. Odajima H, Ebisawa M, Nagakura T, et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int 2015; 64:364-70.
14. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378-81.
15. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013; 162:89-93.
16. Barrios JL, Bégin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and severe atopic dermatitis: A pediatric perspective. J Am Acad Dermatol 2013; 69:832-4.
17. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274-80.
18. Rocklin Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004; 59:973-9.
19. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 2001; 286:2956-67.
20. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91:160- 67.
21. Vignola A, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-17.
22. Kopp M, Hamelmann E, Zielen S, et al; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271-79.
23. Bernstein JA, Saini SS, Maurer M, et al. Efficacy of omalizumab in patients with chronic idiopathic/spontaneous urticaria with different background therapy: post hoc analysis of Asteria I, Asteria II, and Glacial studies. J Allergy Clin Immunol 2014; 2:AB117.
24. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study. J Invest Dermatol 2015; 135:925.
25. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132:101-9.
26. Netchiporouk E, Nguyen CH, Thuraisingham T, Jafarian F, Maurer M, Ben-Shoshan M. Management of pediatric chronic spontaneous and physical urti-caria patients with omalizumab: case series. Pediatr Allergy Immunol 2015; 26:585-88.
27. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127:1622-24.
28. Vitaliti G, Pavone P, Guglielmo F, Falsaperla R. Sublingual immunotherapy in preschool children: An update. Expert Rev Clin Immunol 2013; 9:385-90.
29. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut- Allergic patients. J Allergy Clin Immunol 2013; 132:1368-74.
30. Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, Dias JA. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011; 170:1471-74.